Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
- Conditions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2012-03-15
- Target Recruit Count
- 60
- Registration Number
- NCT00083005
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma
- Conditions
- First Posted Date
- 2004-05-04
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00008242
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
UARK 2003-33, Total Therapy III
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 303
- Registration Number
- NCT00081939
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
An Open Protocol for the Compassionate Use of Thalidomide
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2010-07-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 250
- Registration Number
- NCT00081757
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-08-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019123
- Locations
- 🇺🇸
Medicine Branch, Bethesda, Maryland, United States
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
- Conditions
- First Posted Date
- 2004-04-09
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003754
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 19
- Registration Number
- NCT00005834
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
- Conditions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT00079092
- Locations
- 🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸CCOP - Greenville, Greenville, South Carolina, United States
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 67
- Registration Number
- NCT00006890
- Locations
- 🇺🇸
St. Mary's/Duluth Clinic Health System, Duluth, Minnesota, United States
🇨🇦Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦Moncton Hospital, Moncton, New Brunswick, Canada
Thalidomide in Treating Patients With Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00015990
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.